nach oben

Inflammation

Erschienen in:

09.06.2016 | ORIGINAL ARTICLE

Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell

verfasst von: Dongsheng Mou, Hua Yang, Changhua Qu, Juan Chen, Chaogui Zhang

Erschienen in: Inflammation | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, which mediate glucose and lipid homeostasis by regulating the expression of a large number of transcription factors. Sphingomyelin synthase (SMS) is a key enzyme in the synthesis of sphingomyelin (SM), and its expression and activity have been reported to be associated with atherosclerosis (AS). Although there have been many functional PPAR and SMS studies on atherosclerosis in recent years, few have investigated the correlation between the activation of PPARδ and the activity of SMS. In his study, macrophage-induced foam cells were utilized to model important pathological changes that occur in AS. The influence of PPARδ agonism by GW501516 on SMS and its product molecule SM were measured. Results indicated that the activation of PPARδ was correlated in a positive manner with the activity of SMS2, and the content of SM was dose dependently increased by GW501516. Together, this study represents the first to suggest that PPARδ activation may be a potential risk of AS through enhancing activity of SMS2.

Ajith, T.A., and T.G. Jayakumar. 2016. Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease. Clinical and Experimental Pharmacology & Physiology. doi:10.1111/1440-1681.12579.

Auwerx, J.H., A. Chait, and S.S. Deeb. 1989. Regulation of the low density lipoprotein receptor and hydroxymethylglutaryl coenzyme A reductase genes by protein kinase C and a putative negative regulatory protein. Proceedings of the National Academy of Sciences of the United States of America 86(4): 1133–1137.CrossRefPubMedPubMedCentral

Auwerx, J.H., S. Deeb, J.D. Brunzell, R. Peng, and A. Chait. 1988. Transcriptional activation of the lipoprotein lipase and apolipoprotein E genes accompanies differentiation in some human macrophage-like cell lines. Biochemistry 27(8): 2651–2655.CrossRefPubMed

Bligh, E.G., and W.J. Dyer. 1959. A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37(8): 911–917. doi:10.1139/o59-099.CrossRefPubMed

Bojic, L.A., A.C. Burke, S.S. Chhoker, D.E. Telford, B.G. Sutherland, J.Y. Edwards, C.G. Sawyez, et al. 2014. Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology 34(1): 52–60. doi:10.1161/ATVBAHA.113.301830.CrossRefPubMed

Briand, F., S.U. Naik, I. Fuki, J.S. Millar, C. Macphee, M. Walker, J. Billheimer, G. Rothblat, and D.J. Rader. 2009. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clinical and Translational Science 2(2): 127–133.CrossRefPubMedPubMedCentral

Cheang, W.S., X.Y. Tian, W.T. Wong, and Y. Huang. 2015. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. British Journal of Pharmacology 172(23): 5512–5522. doi:10.1111/bph.13029.CrossRefPubMed

Choi, Y.J., B.K. Roberts, X. Wang, J.C. Geaney, S. Naim, K. Wojnoonski, D.B. Karpf, and R.M. Krauss. 2012. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220(2): 470–476. doi:10.1016/j.atherosclerosis.2011.10.029.CrossRefPubMed

Ding, T., Z. Li, T. Hailemariam, S. Mukherjee, F.R. Maxfield, M.P. Wu, and X.C. Jiang. 2008. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis. Journal of Lipid Research 49(2): 376–385. doi:10.1194/jlr.M700401-JLR200.CrossRefPubMed

10.

Dong, J., J. Liu, B. Lou, Z. Li, X. Ye, M. Wu, and X.C. Jiang. 2006. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. Journal of Lipid Research 47(6): 1307–1314. doi:10.1194/jlr.M600040-JLR200.CrossRefPubMed

11.

Graham, T.L., C. Mookherjee, K.E. Suckling, C.N. Palmer, and L. Patel. 2005. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(−/−) mice. Atherosclerosis 181(1): 29–37. doi:10.1016/j.atherosclerosis.2004.12.028.CrossRefPubMed

12.

Guyton, J.R., and K.F. Klemp. 1996. Development of the lipid-rich core in human atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 16(1): 4–11.CrossRefPubMed

13.

Hailemariam, T.K., C. Huan, J. Liu, Z. Li, C. Roman, M. Kalbfeisch, H.H. Bui, et al. 2008. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arteriosclerosis, Thrombosis, and Vascular Biology 28(8): 1519–1526. doi:10.1161/ATVBAHA.108.168682.CrossRefPubMed

14.

Hoff, H.F., and R.E. Morton. 1985. Lipoproteins containing apo B extracted from human aortas. Structure and function. Annals of the New York Academy of Sciences 454: 183–194.CrossRefPubMed

15.

Hojjati, M.R., and X.C. Jiang. 2006. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. Journal of Lipid Research 47(3): 673–676. doi:10.1194/jlr.D500040-JLR200.CrossRefPubMed

16.

Hojjati, M.R., Z. Li, H. Zhou, S. Tang, C. Huan, E. Ooi, S. Lu, and X.C. Jiang. 2005. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. The Journal of Biological Chemistry 280(11): 10284–10289. doi:10.1074/jbc.M412348200.CrossRefPubMed

17.

Huitema, K., J. van den Dikkenberg, J.F. Brouwers, and J.C. Holthuis. 2004. Identification of a family of animal sphingomyelin synthases. The EMBO Journal 23(1): 33–44. doi:10.1038/sj.emboj.7600034.CrossRefPubMed

18.

Jeong, Ts, S.L. Schissel, I. Tabas, H.J. Pownall, A.R. Tall, and X. Jiang. 1998. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. The Journal of Clinical Investigation 101(4): 905–912. doi:10.1172/JCI870.CrossRefPubMedPubMedCentral

19.

Jiang, X.C., F. Paultre, T.A. Pearson, R.G. Reed, C.K. Francis, M. Lin, L. Berglund, and A.R. Tall. 2000. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 20(12): 2614–2618.CrossRefPubMed

20.

Kersten, S., B. Desvergne, and W. Wahli. 2000. Roles of PPARs in health and disease. Nature 405(6785): 421–424. doi:10.1038/35013000.CrossRefPubMed

21.

Lee, C.H., P. Olson, A. Hevener, I. Mehl, L.W. Chong, J.M. Olefsky, F.J. Gonzalez, et al. 2006. PPARdelta regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America 103(9): 3444–3449. doi:10.1073/pnas.0511253103.CrossRefPubMedPubMedCentral

22.

Lee, S.S., T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz, P.M. Fernandez-Salguero, H. Westphal, and F.J. Gonzalez. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 15(6): 3012–3022.CrossRefPubMedPubMedCentral

23.

Li, G., C. Chen, S.D. Laing, C. Ballard, K.C. Biju, R.L. Reddick, R.A. Clark, and S. Li. 2016. Hematopoietic knockdown of PPARdelta reduces atherosclerosis in LDLR^−/− mice. Gene Therapy 23(1): 78–85. doi:10.1038/gt.2015.78.CrossRefPubMed

24.

Li, Y.L., X.Y. Qi, H. Jiang, X.D. Deng, Y.P. Dong, T.B. Ding, L. Zhou, et al. 2015. Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. Bioorganic and Medicinal Chemistry 23(18): 6173–6184. doi:10.1016/j.bmc.2015.07.060.CrossRefPubMed

25.

Li, Z., T.K. Hailemariam, H. Zhou, Y. Li, D.C. Duckworth, D.A. Peake, Y. Zhang, M.S. Kuo, G. Cao, and X.C. Jiang. 2007. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochimica et Biophysica Acta 1771(9): 1186–1194. doi:10.1016/j.bbalip.2007.05.007.CrossRefPubMedPubMedCentral

26.

Liu, J., H. Zhang, Z. Li, T.K. Hailemariam, M. Chakraborty, K. Jiang, D. Qiu, et al. 2009. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 29(6): 850–856. doi:10.1161/ATVBAHA.109.185223.CrossRefPubMedPubMedCentral

27.

Merrill Jr., A.H., and D.D. Jones. 1990. An update of the enzymology and regulation of sphingomyelin metabolism. Biochimica et Biophysica Acta 1044(1): 1–12.CrossRefPubMed

28.

Miyaji, M., Z.X. Jin, S. Yamaoka, R. Amakawa, S. Fukuhara, S.B. Sato, T. Kobayashi, et al. 2005. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. The Journal of Experimental Medicine 202(2): 249–259. doi:10.1084/jem.20041685.CrossRefPubMedPubMedCentral

29.

Motojima, K., P. Passilly, J.M. Peters, F.J. Gonzalez, and N. Latruffe. 1998. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. The Journal of Biological Chemistry 273(27): 16710–16714.CrossRefPubMed

30.

Nakamura, F., Y. Ishida, D. Sawada, N. Ashida, T. Sugawara, M. Sakai, T. Goto, T. Kawada, and S. Fujiwara. 2016. Fragmented lactic acid bacterial cells activate peroxisome proliferator-activated receptors and ameliorate dyslipidemia in obese mice. Journal of Agricultural and Food Chemistry 64(12): 2549–2559. doi:10.1021/acs.jafc.5b05827.CrossRefPubMed

31.

Naya, N., K. Fukao, A. Nakamura, T. Hamada, M. Sugimoto, M. Kojima, N. Yoshimura, et al. 2016. A selective peroxisome proliferator-activated receptor delta agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice. Metabolism 65(1): 16–25. doi:10.1016/j.metabol.2015.09.016.CrossRefPubMed

32.

Noel, C., Y.L. Marcel, and J. Davignon. 1972. Plasma phospholipids in the different types of primary hyperlipoproteinemia. The Journal of Laboratory and Clinical Medicine 79(4): 611–621.PubMed

33.

Oliver Jr., W.R., J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 98(9): 5306–5311. doi:10.1073/pnas.091021198.CrossRefPubMedPubMedCentral

34.

Park, T.S., R.L. Panek, S.B. Mueller, J.C. Hanselman, W.S. Rosebury, A.W. Robertson, E.K. Kindt, R. Homan, S.K. Karathanasis, and M.D. Rekhter. 2004. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 110(22): 3465–3471. doi:10.1161/01.CIR.0000148370.60535.22.CrossRefPubMed

35.

Park, T.S., R.L. Panek, M.D. Rekhter, S.B. Mueller, W.S. Rosebury, A. Robertson, J.C. Hanselman, E. Kindt, R. Homan, and S.K. Karathanasis. 2006. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189(2): 264–272. doi:10.1016/j.atherosclerosis.2005.12.029.CrossRefPubMed

36.

Peters, J.M., N. Hennuyer, B. Staels, J.C. Fruchart, C. Fievet, F.J. Gonzalez, and J. Auwerx. 1997. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. The Journal of Biological Chemistry 272(43): 27307–27312.CrossRefPubMed

37.

Peters, J.M., S.S. Lee, W. Li, J.M. Ward, O. Gavrilova, C. Everett, M.L. Reitman, L.D. Hudson, and F.J. Gonzalez. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Molecular and Cellular Biology 20(14): 5119–5128.CrossRefPubMedPubMedCentral

38.

Rodriguez, J.L., G.C. Ghiselli, D. Torreggiani, and C.R. Sirtori. 1976. Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1. Chemical composition of very low density lipoproteins in rabbits. Atherosclerosis 23(1): 73–83.CrossRefPubMed

39.

Spiegelman, B.M. 1998. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47(4): 507–514.CrossRefPubMed

40.

Sprecher, D.L., C. Massien, G. Pearce, A.N. Billin, I. Perlstein, T.M. Willson, D.G. Hassall, et al. 2007. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 27(2): 359–365. doi:10.1161/01.ATV.0000252790.70572.0c.CrossRefPubMed

41.

Tafesse, F.G., P. Ternes, and J.C. Holthuis. 2006. The multigenic sphingomyelin synthase family. The Journal of Biological Chemistry 281(40): 29421–29425. doi:10.1074/jbc.R600021200.CrossRefPubMed

42.

Takata, Y., J. Liu, F. Yin, A.R. Collins, C.J. Lyon, C.H. Lee, A.R. Atkins, et al. 2008. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 105(11): 4277–4282. doi:10.1073/pnas.0708647105.CrossRefPubMedPubMedCentral

43.

Toral, M., M. Gomez-Guzman, R. Jimenez, M. Romero, M.J. Zarzuelo, M.P. Utrilla, C. Hermenegildo, et al. 2015. Chronic peroxisome proliferator-activated receptor beta/delta agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. Journal of Hypertension 33(9): 1831–1844. doi:10.1097/HJH.0000000000000634.CrossRefPubMed

44.

Van der Luit, A.H., M. Budde, S. Zerp, W. Caan, J.B. Klarenbeek, M. Verheij, and W.J. Van Blitterswijk. 2007. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. The Biochemical Journal 401(2): 541–549. doi:10.1042/BJ20061178.CrossRefPubMed

45.

Wallace, J.M., M. Schwarz, P. Coward, J. Houze, J.K. Sawyer, K.L. Kelley, A. Chai, and L.L. Rudel. 2005. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. Journal of Lipid Research 46(5): 1009–1016. doi:10.1194/jlr.M500002-JLR200.CrossRefPubMed

46.

Wang, Y.X., C.H. Lee, S. Tiep, R.T. Yu, J. Ham, H. Kang, and R.M. Evans. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113(2): 159–170.CrossRefPubMed

47.

Yan, N., T. Ding, J. Dong, Y. Li, and M. Wu. 2011. Sphingomyelin synthase overexpression increases cholesterol accumulation and decreases cholesterol secretion in liver cells. Lipids in Health and Disease 10: 46. doi:10.1186/1476-511X-10-46.CrossRefPubMedPubMedCentral

Titel: Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell
verfasst von: Dongsheng Mou
Hua Yang
Changhua Qu
Juan Chen
Chaogui Zhang
Publikationsdatum: 09.06.2016
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 4/2016
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-016-0389-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Lipopolysaccharide-Induced Behavioral Alterations Are Alleviated by Sodium Phenylbutyrate via Attenuation of Oxidative Stress and Neuroinflammatory Cascade

Anti-Inflammation Effects and Potential Mechanism of Saikosaponins by Regulating Nicotinate and Nicotinamide Metabolism and Arachidonic Acid Metabolism

Coptisine Prevented IL-β-Induced Expression of Inflammatory Mediators in Chondrocytes

Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling

The Role of the T lymphocytes and Remodeling in Asthma

PGRN Suppresses Inflammation and Promotes Autophagy in Keratinocytes Through the Wnt/β-Catenin Signaling Pathway

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin